BioSil (Choline-stabilized orthosilicic acid)

BioSil is a patented form of choline-stabilized orthosilicic acid (ch-OSA) that delivers bioavailable silicon directly to connective tissues. It activates prolyl hydroxylase, a key enzyme in collagen synthesis, while also stimulating fibroblast activity to increase dermal collagen and elastin production.

Origin & History

BioSil is a branded dietary supplement containing ch-OSA (choline-stabilized orthosilicic acid), a bioavailable form of silicon where orthosilicic acid is stabilized by choline to prevent polymerization. The silicon originates from sand (silicon dioxide) and is synthesized as a chemical complex with choline chloride, not extracted from any specific plant or organism.

Historical & Cultural Context

No historical or traditional medicinal use exists for ch-OSA or BioSil, as it is a patented modern synthetic formulation. While silicon occurs naturally in foods and beverages like beer and mineral water, this stabilized form lacks documented use in traditional medicine systems.

Health Benefits

• Increased skin elasticity by 8.5% after 20 weeks (double-blind RCT, n=50)
• Enhanced collagen production as measured by dermal hydroxyproline levels (clinical evidence)
• Stronger hair and reduced hair brittleness (reported in clinical trials)
• Improved nail strength and reduced brittleness (clinical trial reports)
• Potential bone density support (product claims reference trials, specific data not detailed)

How It Works

Choline-stabilized orthosilicic acid delivers silicon in the bioavailable orthosilicic acid (Si(OH)4) form, which activates prolyl hydroxylase, the enzyme responsible for hydroxylating proline residues during collagen triple-helix formation. This stabilization of collagen precursors increases dermal hydroxyproline content, a direct biomarker of net collagen deposition. Additionally, silicon ions stimulate dermal fibroblasts to upregulate elastin and glycosaminoglycan synthesis, improving the structural integrity of the extracellular matrix.

Scientific Research

A key double-blind, placebo-controlled RCT (PMID: 16205932) tested 10 mg Si/day of ch-OSA in 50 women over 20 weeks, demonstrating significantly increased skin elasticity and dermal collagen markers versus placebo with no adverse effects. Product literature references additional double-blind trials for hair, nails, and bone density, though specific PMIDs are not provided in available sources.

Clinical Summary

A double-blind, placebo-controlled RCT (n=50) demonstrated a statistically significant 8.5% increase in skin elasticity after 20 weeks of ch-OSA supplementation at 10 mg/day. The same trial measured increased dermal hydroxyproline levels, confirming enhanced collagen biosynthesis rather than merely subjective improvement. Separate clinical trials have reported reductions in hair brittleness and improved nail strength, though these studies tend to have smaller sample sizes and shorter durations. Overall evidence quality is moderate; results are promising but replication in larger, independent trials is needed to confirm long-term efficacy.

Nutritional Profile

BioSil (Choline-stabilized orthosilicic acid) is a specialized bioactive supplement, not a food-based ingredient, and therefore contains no meaningful macronutrients (carbohydrates, fats, or proteins) in functional quantities. Active compound: orthosilicic acid (OSA) — the monomeric, water-soluble form of silicon (Si), stabilized with choline chloride to prevent polymerization into insoluble silica. Typical liquid drop formulation delivers approximately 5 mg of elemental silicon per serving (6 drops), with choline contributing approximately 100 mg per serving as the stabilizing carrier molecule. Silicon concentration in BioSil liquid is approximately 6.7 mg/mL. Orthosilicic acid (Si(OH)4) represents the bioavailable fraction of silicon; bioavailability of OSA from this formulation is reported at approximately 64% absorption in human studies, substantially higher than dietary silicon sources (e.g., silica from plant foods ~4% bioavailability, silicon from water ~50%). Choline component contributes to phospholipid synthesis and methyl-group metabolism as a secondary benefit. No significant vitamins, dietary minerals, fiber, or protein content. Silicon in OSA form acts as a biochemical cofactor supporting hydroxylation enzymes involved in collagen cross-linking (prolyl and lysyl hydroxylases) and glycosaminoglycan synthesis. Caloric content is negligible (<1 kcal per serving).

Preparation & Dosage

Clinically studied dosage: 10 mg silicon (as ch-OSA) per day, typically split into morning/evening doses. Available forms include: liquid drops (5 mg Si per 5 drops, twice daily), capsules (6 mg Si per capsule), and vegan mini-capsules (5 mg Si per capsule). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Biotin, Collagen peptides, Hyaluronic acid, MSM

Safety & Interactions

BioSil at the clinically studied dose of 10 mg silicon per day is generally well tolerated, with no serious adverse events reported in published trials. The choline carrier component may interact with cholinergic medications or supplements, and individuals sensitive to choline should exercise caution. There are no well-documented contraindications for healthy adults, but silicon-containing supplements are not recommended for individuals with chronic kidney disease, as impaired renal clearance may lead to silicon accumulation. Safety data in pregnant or breastfeeding women is insufficient, so use during pregnancy should be avoided without physician guidance.